The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...

There are three types of intravesical immunotherapies for bladder cancer: BCG treatment is the most common immunotherapy for cancer and is often the first-line option for bladder cancer.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who ...

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

The standard first-line treatment is transurethral resection of the bladder tumor (TURBT) followed by intravesical BCG immunotherapy. However, a significant proportion of patients experience ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...

Administered into the bladder via intravesical instillation using ... particularly in patients unresponsive to BCG therapy. The therapy has received FDA Fast Track Designation, reflecting its ...